六味五灵片联合恩替卡韦治疗活动性乙型肝炎肝硬化的疗效研究  

Clinical study of liuweiwuling tablets combined with entecavir in the treatment of patients with cirrhosis induced by active hepatitis B

作　　者：高爱华[1] 张凤朝[1] 

机构地区：[1]河北省沧州市传染病医院肝病一科,061001

出　　处：《临床合理用药杂志》2012年第35期15-16,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的探讨六味五灵片联合恩替卡韦治疗乙型肝炎肝硬化的疗效。方法选择210例活动性乙型肝炎肝硬化患者,随机分为治疗组105例,应用六味五灵片联合恩替卡韦治疗;对照组105例单用恩替卡韦治疗。观察治疗24周及48周时的ALT、AST、TBIL、HBV-DNA转阴率及治疗前后肝纤维化指标变化。结果治疗24周及48周后,治疗组及对照组2组的ALT、AST、TBIL值均与治疗前比较差异有统计学意义(P<0.05),且治疗组与对照组间比较差异有统计学意义(P<0.05)。治疗组治疗24周HBV-DNA阴转率93.3%,对照组阴转率70.5%,差异有统计学意义(P<0.05)。治疗组总有效率为92.4%,对照组总有效率为69.5%,2组差异显著有统计学意义(P<0.01)。结论六味五灵片联合恩替卡韦治疗活动性乙型肝炎肝硬化具有一定的协同作用,疗效明确,安全性较好。Objective To evaluate the clinical effect of liuweiwuling tablet combined with Entecavir in the treatment of patients with hepatitis B-related liver cirrhosis.Methods 210 patients with chronic hepatitis B-related liver cirrhosis were randomly divided into two groups,the treatment group（n=105） was received liuweiwuling tablet combined with Entecavir for treatment;the control group （n=105） was received Entecavir only.The index of ALT、AST、TBIL、the negative conversion ratio of HBV DNA and serum index of liver fibrosis were tested before and the 24weeks and 48weeks after treatment.Results 24weeks and 48weeks after treatment,the differences of ALT、AST、TBIL in 2 groups were statistically significant compared with before treatment （P0.05）,and there were significant difference between the2 groups （P0.05）.The negative conversion ratio of HBV DNA 24weeks after treatment was 93.3%,which was higher than 70.5% of the control group,and the difference was statistically significant （P0.05）.After treatment,the total effective rates of the treatment group was 92.4%,while it was 69.5% in the control group,and there is significant difference between the 2 groups （P0.01）.Conclusion Liuweiwuling tablet combined with Entecavir has a positive effect for patients with hepatitis B-related liver cirrhosis,and the safety of which was better.

关 键 词：六味五灵片 恩替卡韦 活动性 乙型肝炎 肝硬化 

分 类 号：R512.62[医药卫生—内科学]